Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “
Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald set a $23.00 price objective on Corvus Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, August 6th. BTIG Research assumed coverage on Corvus Pharmaceuticals in a research report on Thursday, June 2nd. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Corvus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $21.60.
Corvus Pharmaceuticals (NASDAQ:CRVS) traded up 3.94% during midday trading on Thursday, hitting $15.57. The company had a trading volume of 15,177 shares. The stock’s market capitalization is $325.55 million. The stock has a 50 day moving average price of $14.32 and a 200-day moving average price of $13.86. Corvus Pharmaceuticals has a 52 week low of $9.63 and a 52 week high of $16.62.
Large investors have recently modified their holdings of the stock. State Street Corp bought a new position in Corvus Pharmaceuticals during the second quarter valued at approximately $407,000. FMR LLC raised its position in Corvus Pharmaceuticals by 5.3% in the second quarter. FMR LLC now owns 2,311,297 shares of the company’s stock valued at $32,959,000 after buying an additional 116,500 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Corvus Pharmaceuticals by 1,081.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 35,734 shares of the company’s stock valued at $510,000 after buying an additional 32,710 shares during the last quarter. BlackRock Fund Advisors bought a new position in Corvus Pharmaceuticals during the second quarter valued at approximately $1,248,000. Finally, BlackRock Investment Management LLC raised its position in Corvus Pharmaceuticals by 143.0% in the second quarter. BlackRock Investment Management LLC now owns 12,394 shares of the company’s stock valued at $177,000 after buying an additional 7,294 shares during the last quarter. 82.91% of the stock is owned by institutional investors and hedge funds.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.